Viridian Therapeutics, Inc.\DE Income Statement (2014-2026) | VRDN

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	1.09M	0.21M	0.21M	0.22M	0.26M	1.20M	0.10M	0.10M	0.07M	0.07M	0.07M	0.07M	0.07M	0.09M	0.07M	0.07M	0.07M	70.57M	0.13M	0.14M
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)	12.56M	8.12M	22.39M	17.75M	21.71M	22.12M	5.60M	50.74M	40.08M	30.39M	38.56M	40.94M	56.19M	69.16M	71.96M	76.83M	86.63M	86.26M	10.00M	77.63M
Selling, General & Administrative (Quarter)	6.52M	6.22M	6.90M	8.36M	8.11M	8.86M	9.85M	21.83M	19.26M	20.91M	32.99M	15.03M	16.07M	14.41M	15.58M	17.10M	20.22M	24.32M	33.67M	38.68M
Other Operating Expenses (Quarter)							33.72M							-0.20M	-0.26M			0.45M	-2.12M	-0.67M
Operating Expenses (Quarter)	19.09M	14.34M	29.30M	26.11M	29.82M	30.98M	49.17M	72.57M	59.35M	51.30M	71.55M	55.97M	72.26M	83.57M	87.54M	93.94M	106.84M	110.58M	122.88M	116.31M
Operating Income (Quarter)	-18.00M	-14.13M	-29.08M	-25.89M	-29.56M	-29.79M	-49.07M	-72.47M	-59.27M	-51.22M	-71.48M	-55.90M	-72.19M	-83.48M	-87.47M	-93.87M	-106.77M	-40.01M	-122.75M	-116.17M
EBIT (Quarter)																				-116.17M
Non-operating items
Interest & Investment Income (Quarter)	0.03M	0.09M	0.14M	0.20M	0.23M	1.04M	3.45M	4.49M	4.38M	4.16M	5.21M	7.94M	7.79M	7.51M	8.52M	7.54M	6.55M	5.52M	7.79M	7.87M
Other Non Operating Income (Quarter)																				7.53M
Non Operating Income (Quarter)																				11.27M
Net income details
EBT (Quarter)																				-111.76M
Profit After Tax (Quarter)																				-104.90M
Income from Continuing Operations (Quarter)																				-111.76M
Consolidated Net Income (Quarter)																				-111.76M
Income towards Parent Company (Quarter)																				-111.76M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)																				-111.76M
Additional items
EPS (Basic) (Quarter)																				-0.90
EPS (Weighted Average and Diluted) (Quarter)																				-60.02
Shares Outstanding (Weighted Average) (Quarter)																				0.08M
Shares Outstanding (Diluted Average) (Quarter)																				0.08M
EBITDA (Quarter)																				-105.91M
Interest Expenses (Quarter)																				3.46M
Shares Outstanding (Quarter)																				102.46M

Research Tools

Viridian Therapeutics, Inc.\DE Income Statement (2014-2026) | VRDN

Create an account

Sign In

Reset Password